Finland's Tamro group reports turnover of 4.1 billion markka ($880.0 million) for the first four months of 1996, a rise of 19.7%, with operating profits rising 21.8% to 79 million markka and pretax profits at 76 million markka, or 28.8% higher than in the like, year-earlier period.
Tamro's pharmaceutical distribution division saw sales jump 19.9% to 3.82 billion markka ($820.7 million) and operating profits rise 8.3% to 52 million markka. Hospital and laboratory division sales were 162 million markka, up 17.4%, and in this unit operating margins improved from 18 million markka to 21 million markka, the company said.
The Swedish market accounts for 70% of Tamro's pharmaceutical distribution division, Finland for 28%, Norway about 1% and the Baltic states and the St Petersburg region also about 1%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze